ReviewInternational journal of chronic obstructive pulmonary disease2008
Formoterol in the management of chronic obstructive pulmonary disease.
Review in International journal of chronic obstructive pulmonary disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.Advances in therapy · 2019Pooled it
- Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD.International journal of chronic obstructive pulmonary disease · 2011Trial
- Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis.BMC pulmonary medicine · 2017Article
- Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2016Review
- New combinations in the treatment of COPD: rationale for aclidinium-formoterol.Therapeutics and clinical risk management · 2016Review
- New developments in the management of COPD: clinical utility of indacaterol 75 μg.International journal of chronic obstructive pulmonary disease · 2014Review
- "Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD.BMC pulmonary medicine · 2010Article
- Nebulized formoterol: a review of clinical efficacy and safety in COPD.International journal of chronic obstructive pulmonary disease · 2010Review
- COPD exacerbation: lost in translation.BMC pulmonary medicine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchodilators represent the hallmark of symptomatic treatment of Chronic Obstructive Pulmonary Disease (COPD). There are four categories of bronchodilators: anticholinergics, methylxanthines, short-acting beta2-agonists, and long-acting beta2-agonists such as formoterol. Significant research has been performed to investigate the efficacy, safety and tolerability of formoterol in the therapeutic field of COPD. Formoterol exhibits a rapid onset of bronchodilation similar to that observed with salbutamol, yet its long bronchodilatory duration is comparable to salmeterol. In addition, formoterol presents with a clear superiority in lung function improvement compared with either ipratropium bromide or oral theophylline, while its efficacy improves when administered in combination with ipratropium. Formoterol has been shown to better reduce dynamic hyperinflation, which is responsible for exercise intolerance and dyspnea in COPD patients, compared with other bronchodilators, whereas it exerts synergistic effect with tiotropium. Moreover, formoterol reduces exacerbations, increases days free of use of rescue medication and improves patients' quality of life and disease symptoms. Formoterol has a favorable safety profile and is better tolerated than theophylline. Collectively, data extracted from multicenter clinical trials support formoterol as a valid therapeutic option in the treatment of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.